IGC Pharma Sees Price Target Boost as Alzheimer's Clinical Trials Advance

New York, Wednesday, 8 April 2026.
Sparked by advancing Phase 2 Alzheimer’s trials, Ascendiant Capital Markets raised IGC Pharma’s price target to $5.25 on April 8, 2026, signaling strong confidence in its AI-driven medical pipeline.